196 related articles for article (PubMed ID: 23798615)
1. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Izzedine H; Escudier B; Rouvier P; Gueutin V; Varga A; Bahleda R; Soria JC
Ann Oncol; 2013 Sep; 24(9):2421-5. PubMed ID: 23798615
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin Is Not Protective against Ischemic and Cisplatin-Induced Kidney Injury.
Andrianova NV; Zorova LD; Babenko VA; Pevzner IB; Popkov VA; Silachev DN; Plotnikov EY; Zorov DB
Biochemistry (Mosc); 2019 Dec; 84(12):1502-1512. PubMed ID: 31870254
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Bozas G; Roy A; Ramasamy V; Maraveyas A
Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer.
Vootukuru V; Liew YP; Nally JV
Med Oncol; 2006; 23(3):419-22. PubMed ID: 17018900
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-induced acute kidney injury leading to chronic kidney disease.
Chauvet S; Courbebaisse M; Ronco P; Plaisier E
Clin Nephrol; 2014 Dec; 82(6):402-6. PubMed ID: 24424085
[TBL] [Abstract][Full Text] [Related]
6. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.
Sbitti Y; Chahdi H; Slimani K; Debbagh A; Mokhlis A; Albouzidi A; Bennani F; Errihani H; Ichou M
J Med Case Rep; 2017 Jul; 11(1):182. PubMed ID: 28750665
[TBL] [Abstract][Full Text] [Related]
7. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
Winn SK; Ellis S; Savage P; Sampson S; Marsh JE
Nephrol Dial Transplant; 2009 Feb; 24(2):673-5. PubMed ID: 19039026
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
10. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
Xu ZZ; Shen JK; Zhao SQ; Li JM
Leuk Lymphoma; 2018 Jun; 59(6):1451-1460. PubMed ID: 28952842
[TBL] [Abstract][Full Text] [Related]
13. [Zoledronate-associated end stage renal failure and hypocalcaemia].
Ramazzina C; Zysset Aschmann Y; Kummer O; Rätz Bravo AE; Bodmer M
Praxis (Bern 1994); 2007 Apr; 96(17):673-6; quiz 677-8. PubMed ID: 17491196
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
15. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008].
de Marinis F; Ricciardi S
Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963
[No Abstract] [Full Text] [Related]
16. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
17. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
18. Allergic interstitial nephritis possibly related to sunitinib use.
Khurana A
Am J Geriatr Pharmacother; 2007 Dec; 5(4):341-4. PubMed ID: 18179992
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
